Aptar Pharma announced that it has signed a development and promotion agreement with Pulmotree related to Pulmotree’s Kolibri mesh nebulizer, which it refers to as a non-propellant liquid inhaler (NPLI) platform. The company says that its subsidiaries, including inhalation CRO Nanopharm and human factors specialist Noble, will support Kolibri development projects for customers.
The Kolibri is a breath-activated, connected device that provides real-time inhalation technique feedback. Pulmotree also says that the Kolibri has a “key-& lock-system” to prevent inadvertent switching of the nebulizer head.
Aptar Pharma VP, Global Pulmonary Category, Howard Burnett, commented, “Pulmotree has solid experience in the NPLI field and Aptar Pharma is delighted to be able to offer the Kolibri technology in collaboration with such a knowledgeable partner, to be able to provide full support to all drug developers, from formulation development to patient onboarding.”
Pulmotree CEO Ulf Krüger said, “With this alliance, pharmaceutical partners can access an unprecedented portfolio of services from Aptar Pharma as a single source, in the development of combination products to accelerate product development. For Pulmotree, this important step enables us to continue to grow sustainably and expand our portfolio.”
Read the Aptar Pharma press release.
